Figure 5. In vivo anti-tumor ability of B7-H3Bi-armed ATC in mouse subcutaneous cancer model.
SCID/Beige mice were inoculated subcutaneously with 1×106 Hela-luc cells. On day 1, 2, 6, 12 and 14, tumor-bearing mice were locally treated with 2×107 B7-H3Bi-armed ATC or unarmed ATC (each group contains 5 mice). Tumor growth was monitored using an in vivo imaging system A. Bioluminescence images of 3 representative mice of each group were shown on indicated day. B. Images were analyzed using Living Image software and tumor values represented as total flux measurements in photons/second, mean values of tumor growth curves were shown. C. Survival curves of mice engrafted with Hela-luc tumor cells receiving B7-H3Bi-armed ATC or unarmed ATC were shown. *P < 0.05, **P < 0.01, B7-H3Bi-armed ATC was compared with unarmed ATC under similar conditions.